Temozolomide plus thalidomide in patients with brain metastases from melanoma
Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Alan N. Houghton(Eastern Cooperative Oncology Group), Lynne Lamb(Memorial Sloan Kettering Cancer Center), Eric Lis(Memorial Sloan Kettering Cancer Center), Philip O. Livingston(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Katherine S. Panageas(Mayo Clinic), Linda Williams(Edinburgh Cancer Research), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Janene Merrell(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Jennifer H. Menell
Cited by 102
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k